Investors wait for ailing CSL to recover

ANALYSIS: The past three years have been a disaster for CSL as the company’s share price has more than halved. Is there any more bad news to come, or has the company been oversold?

WATCH: NBR senior journalist Lachlan Colquhoun speaks with Simon Shepherd

Back in October 2023, and shortly after this particular Shoeshine joined NBR, he penned a column about Australian bio-tech giant CSL Ltd.

Back then, the company’s shares were on the slide, travelling at just over A$230, which was causing consternation in the market as they had fallen 25% in three

Want to read more? It's easy.

Choose your subscription

Already have an account? Login

Smartphone Only Subscription

NZ$29.95 / monthly

Monthly Premium Online Subscription

NZ$49.95 / monthly

Smartphone Only Annual Subscription

NZ$299.00 / yearly

Yearly Premium Online Subscription

NZ$499.00 / yearly

Premium Group Membership 10 Users

NZ$385+GST / monthly

$38.5 per user - Pay by monthly credit card debit

Premium Group Membership 20 Users

NZ$660+GST / monthly

$33 per user - Pay by monthly credit card debit

Premium Group Membership 50 Users

NZ$1375+GST / monthly

$27.5 per user - Pay by monthly credit card debit

Premium Group Membership 100 Users

NZ$2100+GST / monthly

$21 per user - Pay by monthly credit card debit

Yearly Premium Online Subscription + NBR Marketplace

NZ$999.00 / yearly

Individual

Group membership

NBR Marketplace

Student

Exclusive FREE offer for uni students studying at a New Zealand university (valued at $499).

View terms and conditions.

Lachlan Colquhoun Mon, 25 May 2026

Contact the Writer: lachlan@nbr.co.nz

News tip? Question? Typo? Let us know: editor@nbr.co.nz

Categories

Analysis

Featured